An Open-Label Prospective, Non-Comparative Study to Explore the Tolerability, Safety and Effectiveness Upon Transition to Paliperidone ER in Patients With Schizophrenia.

Trial Profile

An Open-Label Prospective, Non-Comparative Study to Explore the Tolerability, Safety and Effectiveness Upon Transition to Paliperidone ER in Patients With Schizophrenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2014

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms PERFECT
  • Sponsors Janssen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Mar 2011 Planned end date changed from 1 Nov 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top